Drugs / florbetapir
florbetapir
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02120664 | Apr 2014 → Sep 2015 | Alzheimer disease | Avid Radiopharmaceuticals | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04588649 | Jan → Mar 2016 | cerebrovascular disorder, dementia | Chang Gung Memorial Hospital | Completed | No outcome recorded |
| Phase 2 | NCT02039024 | Mar 2012 → Dec 2015 | Parkinson disease | Chang Gung Memorial Hospital | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02016560 | Dec 2013 → Jul 2017 | Alzheimer disease | Avid Radiopharmaceuticals | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT02813434 | Sep 2014 → Jan 2025 | dementia | Centre Hospitalier Universitaire, Amiens | Completed | No outcome recorded |
| Phase 3 | NCT02164643 | Jun 2014 → Oct 2019 | Alzheimer disease | University Hospital, Bordeaux | Completed | No outcome recorded |
| Phase 3 | NCT01447719 | Mar 2010 → Mar 2011 | Alzheimer disease | Avid Radiopharmaceuticals | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01606488 | May 2012 → Jun 2026 overdue | — | University of California, San Francisco | Active not recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT01565369 Background | Jan 2011 | Alzheimer disease | Avid Radiopharmaceuticals | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Florbetapir | “During this study, subjects will receive a single i.v. administration of approximately 370MBq (10 mCi) florbetapir F-18 immediately prior to imaging.” NCT02039024 ↗ |
| Known as | (E)-4-(2-(6-(2-(2-(2-\[18F\]fluoroethoxy) ethoxy) ethoxy)pyridin-3-yl)vinyl)-N-methylbenzenamine | “Name: \[18F\]AV-45, (E)-4-(2-(6-(2-(2-(2-\[18F\]fluoroethoxy) ethoxy) ethoxy)pyridin-3-yl)vinyl)-N-methylbenzenamine Dosage form: intravenous injection” NCT04588649 ↗ |
| Known as | \[18F\]AV-45 | “This study is aimed at examining the interest of amyloid radiotracer Florbetapir (18F-AV-45) for the etiological diagnosis of poststroke cognitive impairment and dementia.” NCT02813434 ↗1“\[18F\]AV-45 PET Imaging” NCT04588649 ↗ |
| Known as | AV-45 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04588649 ↗ |
| Known as | Florbetapir F 18 (18F-AV-45) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01606488 ↗ |
| Known as | florbetapir F-18 | “During this study, subjects will receive a single i.v. administration of approximately 370MBq (10 mCi) florbetapir F-18 immediately prior to imaging.” NCT02039024 ↗ |
| Modality | Diagnostic / imaging agent | “The sensitivity and specificity of florbetapir PET imaging for detection of moderate to frequent plaques were” PMID 22749065 ↗ Jun 2012 |
| Route | Intravenous | “IV injection” NCT01565369 ↗ |